Clinical trials in Olomouc – page 6

342 clinical trials in Olomouc, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in CzechiaKlinickeTesty.cz

Olomouc at a glance

342

clinical trials

Research sites1

Quick filters

342 trials in Olomouc

Open in trial search

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Colitis ulcerative

Recruiting

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:RO7837195
Sponsor:Genentech Inc.

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

HER2 positive biliary tract cancer

Recruiting

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Registered drugNo placebo

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Oesophageal cancer metastatic+3

Recruiting

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Olomouc

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple cancer types, including metastatic prostate cancer, lung cancer, and colorectal cancer. Research emphasizes innovative treatment approaches and combination therapies.

Prostate Cancer Treatment Evaluation
Lung Cancer Therapy Development
Cervical Cancer Treatment Comparisons

These trials aim to improve survival rates and treatment effectiveness across various cancer types.

02 Cardiovascular and Metabolic Disorders

Studies investigating treatments for heart failure prevention, obesity management, and cardiovascular disease. Focus on innovative therapeutic approaches and combination treatments.

Heart Failure Prevention Studies
Obesity Treatment Research
Cardiovascular Risk Management

Research aims to reduce cardiovascular events and improve patient outcomes.

03 Immunology and Inflammatory Conditions

Clinical investigations targeting Crohn's disease, chronic rhinosinusitis, and other inflammatory conditions. Studies evaluate novel therapeutic approaches and treatment optimization.

Inflammatory Bowel Disease Therapy
Autoimmune Disease Treatment
Infection Management Studies

Research focuses on improving treatment responses and patient quality of life.

Back to Czechia All countries